Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 Biomarker disease BEFREE Interleukin-33 Predicts Poor Prognosis and Promotes Renal Cell Carcinoma Cell Growth Through its Receptor ST2 and the JNK Signaling Pathway. 29763892 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 Biomarker disease BEFREE MicroRNA-10b Promotes Apoptosis via JNK Pathway in Clear Cell Renal Cell Carcinoma. 29672315 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 Biomarker disease BEFREE RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma. 29864454 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 Biomarker disease BEFREE The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma. 28950257 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 Biomarker disease BEFREE Periostin promotes migration and invasion of renal cell carcinoma through the integrin/focal adhesion kinase/c-Jun N-terminal kinase pathway. 28381189 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 AlteredExpression disease BEFREE Moreover, Mitogen-activated protein kinase 8 (MAP3K8) is direct target of miR-144-3p, while the expression levels of MAP3K8 were inversely correlated with the expression levels of miR-144-3p in RCC tissues. 27717821 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 AlteredExpression disease BEFREE RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma. 24626183 2014
Conventional (Clear Cell) Renal Cell Carcinoma
0.370 GeneticVariation disease UNIPROT